Pan-PIM kinase inhibition provides a novel therapy for treating hematologic cancers

Clinical Cancer Research

Volumn 20, Issue 7, 2014, Pages 1834-1845

  Garcia, Pablo D ^a   Langowski, John L ^a   Wang, Yingyun ^a   Chen, Min ^a   Castillo, Joseph ^a   Fanton, Christie ^a   Ison, Marjorie ^a   Zavorotinskaya, Tatiana ^a   Dai, Yumin ^a   Lu, Jing ^a   Niu, Xiao Hong ^a   Basham, Stephen ^a   Chan, Julie ^a   Yu, Jianjun ^a   Doyle, Michael ^a   Feucht, Paul ^a   Warne, Robert ^a   Narberes, Jamie ^a   Tsang, Tiffany ^a   Fritsch, Christine ^b   Kauffmann, Audrey ^b   Pfister, Estelle ^b   Drueckes, Peter ^b   Trappe, Joerg ^b   Wilson, Christopher ^a   Han, Wooseok ^a   Lan, Jiong ^a   Nishiguchi, Gisele ^a   Lindvall, Mika ^a   Bellamacina, Cornelia ^a   Aycinena, J Alex ^a   Zang, Richard ^a   Holash, Jocelyn ^a   Burger, Matthew T ^a   more..

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; CYTARABINE; LGB 321; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; PAN PIM KINASE; PROTEIN BAD; PROTEIN SERINE THREONINE KINASE; PROTEIN SERINE THREONINE KINASE INHIBITOR; UNCLASSIFIED DRUG; MTOR PROTEIN, HUMAN; ONCOPROTEIN; PIM1 PROTEIN, HUMAN; PIM2 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PROTEIN KINASE PIM 1; TARGET OF RAPAMYCIN KINASE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER REGRESSION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG SPECIFICITY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SOLID TUMOR; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG SCREENING; GENETICS; HEMATOLOGIC NEOPLASMS; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; HEMATOLOGIC NEOPLASMS; HUMANS; MICE; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-PIM-1; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84898756674     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-2062     Document Type: Article

References (31)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2. Brault L, Gasser C, Bracher F, Huber K, Knapp S, Schwaller J. PIM serine/ threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers. Haematologica 2010;95:1004-15.
3. Qian KC, Wang L, Hickey ER, Studts J, Barringer K, Peng C, et al. Structural basis of constitutive activity and a unique nucleotide binding mode of human Pim-1 Kinase. J Biol Chem 2005;280:6130-7. (Pubitemid 40280098)
4. Nawijn MC, Alendar A, Berns A. For better or for worse: the role of Pim oncogenes in tumorigenesis. Nat Rev Cancer 2011;11:23-34.
5. Cuypers HT, Selten G, Quint W, Zijlstra M, Maandag ER, Boelens W, et al. Murine leukemia virus-induced T-cell lymphomagenesis: integration of proviruses in a distinct chromosomal region. Cell 1984;37:141-50. (Pubitemid 14079845)
6. Meeker TC, Nagarajan L, ar-Rushdi A, Croce CM. Cloning and characterization of the human PIM-1 gene: a putative oncogene related to the protein kinases. J Cell Biochem 1987;35:105-12.
7. van der Lugt NM, Domen J, Verhoeven E, Linders K, van der Gulden H, Allen J, et al. Proviral tagging in E mu-myc transgenic mice lacking the Pim-1 proto-oncogene leads to compensatory activation of Pim-2. EMBO J 1995;14:2536-44.
8. Mikkers H, Allen J, Knipscheer P, Romeyn L, Hart A, Vink E, et al. High-throughput retroviral tagging to identify components of specific signaling pathways in cancer. Nat Genet 2002;32:153-9. (Pubitemid 34977211)
9. van Lohuizen M, Verbeek S, Krimpenfort P, Domen J, Saris C, Radaszkiewicz T, et al. Predisposition to lymphomagenesis in pim-1 transgenic mice: cooperation with c-myc and N-myc in murine leukemia virus-induced tumors. Cell 1989;56:673-82. (Pubitemid 19065532)
10. Anizon F, Shtil AA, Danilenko VN, Moreau P. Fighting tumor cell survival: advances in the design and evaluation of Pim inhibitors. Curr Med Chem 2010;17:4114-33.
11. Dakin LA, Block MH, Chen H, et al. Discovery of novel benzylidene-1,3-thiazolidine-2,4-diones as potent and selective inhibitors of the PIM-1, PIM-2, and PIM-3 protein kinases. Bioorg Med Chem Lett 2012;22:4599-604.
12. Morwick T. Pim kinase inhibitors: a survey of the patent literature. Expert Opin Ther Pat 2010;20:193-212.
13. Narlik-Grassow M, Blanco-Aparicio C, Carnero A. The PIM family of serine/threonine kinases in cancer. Med Res Rev 2013;34:136-59.
14. Lu J, Zavorotinskaya T, Dai Y, Niu XN, Castillo J, Sim J, et al. Pim2 is required for maintaining multiple myeloma cell growth through modulating TSC2 phosphorylation. Blood 2013;122:1610-20.
15. Dai M, Wang P, Boyd AD, Kostov B, Athey B, Jones EG, et al. Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res 2005;33:e175.
16. Harbron C, Chang KM, South MC. RefPlus: an R package extending the RMA Algorithm. Bioinformatics 2007;23:2493-4. (Pubitemid 47423851)
17. Manley PW, Drueckes P, Fendrich G, Furet P, Liebetanz J, Martiny-Baron G, et al. Extended kinase profile and properties of the protein kinase inhibitor nilotinib. Biochim Biophys Acta 2010;1804:445-53.
18. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012;483:603 -7.
19. Beis I, Newsholme EA. The contents of adenine nucleotides, phosphagens, and some glycolytic intermediates in resting muscles from vertebrates and invertebrates. Biochem J 1975;152:23-32.
20. Burger MT, Han W, Lan J, Nishigushi G, Bellamacina C, Lindval M, et al. Structure guided optimization, in vitro activity, and in vivo activity of Pan-PIM kinase inhibitors. ACS Med Chem 2013;4:1193-7.
21. Macdonald A, Campbell DG, Toth R, McLauchlan H, Hastie CJ, Arthur JS. Pim kinases phosphorylate multiple sites on Bad and promote 14-3-3 binding and dissociation from Bcl-XL. BMC Cell Biol 2006;7:1.
22. Yan B, Zemskova M, Holder S, Chin V, Kraft A, Koskinen PJ, et al. The PIM-2 kinase phosphorylates BAD on serine 112 and reverses BADinduced cell death. J Biol Chem 2003;278:45358-67. (Pubitemid 37432672)
23. Aho TL, Sandholm J, Peltola KJ, Mankonen HP, Lilly M, Koskinen PJ. Pim-1 kinase promotes inactivation of the pro-apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site. FEBS Lett 2004; 571:43-9. (Pubitemid 38992921)
24. Mamane Y, Petroulakis E, LeBacquer O, Sonenberg N. mTOR, translation initiation, and cancer. Oncogene 2006;25:6416-22.
25. Cen B, Mahajan S, Wang W, Kraft AS. Elevation of receptor tyrosine kinases by small molecule AKT inhibitors in prostate cancer is mediated by Pim-1. Cancer Res 2013;73:3402-11.
26. Zuber J, Radtke I, Pardee TS, Zhao Z, Rappaport AR, Luo W, et al. Mouse models of human AML accurately predict chemotherapy response. Genes Dev 2009;23:877-89.
27. Mikkers H, Nawijn M, Allen J, Brouwers C, Verhoeven E, Jonkers J, et al. Mice deficient for all PIM kinases display reduced body size and impaired responses to hematopoietic growth factors. Mol Cell Biol 2004;24:6104-15. (Pubitemid 38787993)
28. Roboz GJ. Novel approaches to the treatment of acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2011; 2011:43-50.
29. Kelly KR, Espitia CM, Taverna P, Choy G, Padmanabhan S, Nawrocki ST, et al. Targeting PIM kinase activity significantly augments the efficacy of cytarabine. Br J Haematol 2012;156:129-32.
30. Sauvageau M, Miller M, Lemieux S, Lessard J, Hebert J, Sauvageau G. Quantitative expression profiling guided by common retroviral insertion sites reveals novel and cell type specific cancer genes in leukemia. Blood 2008;111:790-9.
31. Theodorou V, Kimm MA, Boer M, Wessels L, Theelen W, Jonkers J, et al. MMTV insertional mutagenesis identifies genes, gene families, and pathways involved in mammary cancer. Nat Genet 2007;39:759-69. (Pubitemid 46848585)